Esperion to Present at Two Investor Conferences in September 2025

Esperion Therapeutics will present at two investor conferences in September 2025, focusing on FDA-approved non-statin medicines and next-generation ATP citrate lyase inhibitors. The presentations will be available via live webcast on Esperion's website, with replays accessible for 90 days. The company's products are designed to address high levels of LDL-C and cardiovascular disease risk.

Esperion Therapeutics, a commercial-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3, 2025, at 9:45 a.m. ET, and the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 2:00 p.m. ET [1].

Esperion specializes in FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. These medications are supported by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients. The company is also developing next-generation ATP citrate lyase inhibitors (ACLYi) and expanding globally through partnerships and pipeline advancements [1].

The presentations will be available via live webcast on Esperion's website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days [1].

Esperion Therapeutics is focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The company continues to build on its success with its next-generation program, which is focused on developing ATP citrate lyase inhibitors (ACLYi) with rational drug design and allosteric mechanisms [1].

References:
[1] https://www.stocktitan.net/news/ESPR/esperion-to-participate-in-upcoming-september-investor-bijl3leqlq2j.html